Jefferies Financial Group Inc. Decreases Position in Amicus Therapeutics, Inc. $FOLD

Jefferies Financial Group Inc. cut its holdings in Amicus Therapeutics, Inc. (NASDAQ:FOLD) by 26.1% in the 3rd quarter, HoldingsChannel.com reports. The firm owned 165,485 shares of the biopharmaceutical company’s stock after selling 58,315 shares during the period. Jefferies Financial Group Inc.’s holdings in Amicus Therapeutics were worth $1,304,000 at the end of the most recent quarter.

Several other institutional investors have also added to or reduced their stakes in FOLD. Vestal Point Capital LP grew its stake in shares of Amicus Therapeutics by 178.4% during the second quarter. Vestal Point Capital LP now owns 11,900,000 shares of the biopharmaceutical company’s stock valued at $68,187,000 after buying an additional 7,625,000 shares during the last quarter. Norges Bank purchased a new position in shares of Amicus Therapeutics in the second quarter worth about $18,540,000. Qube Research & Technologies Ltd lifted its stake in shares of Amicus Therapeutics by 223.9% in the 2nd quarter. Qube Research & Technologies Ltd now owns 3,466,911 shares of the biopharmaceutical company’s stock valued at $19,865,000 after acquiring an additional 2,396,410 shares during the last quarter. State Street Corp lifted its stake in shares of Amicus Therapeutics by 21.5% in the 2nd quarter. State Street Corp now owns 11,568,097 shares of the biopharmaceutical company’s stock valued at $66,285,000 after acquiring an additional 2,049,078 shares during the last quarter. Finally, M&G PLC purchased a new stake in Amicus Therapeutics during the 2nd quarter valued at about $11,310,000.

Insider Buying and Selling

In related news, CEO Bradley L. Campbell sold 77,926 shares of Amicus Therapeutics stock in a transaction on Monday, December 15th. The shares were sold at an average price of $10.86, for a total value of $846,276.36. Following the sale, the chief executive officer owned 1,129,782 shares in the company, valued at $12,269,432.52. The trade was a 6.45% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, insider David Michael Clark sold 25,643 shares of the business’s stock in a transaction on Monday, December 15th. The shares were sold at an average price of $11.00, for a total transaction of $282,073.00. Following the transaction, the insider directly owned 271,332 shares in the company, valued at approximately $2,984,652. The trade was a 8.63% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last 90 days, insiders have sold 226,711 shares of company stock valued at $2,887,822. 2.20% of the stock is owned by corporate insiders.

Amicus Therapeutics Stock Up 0.1%

NASDAQ FOLD opened at $14.37 on Thursday. Amicus Therapeutics, Inc. has a 1 year low of $5.51 and a 1 year high of $14.39. The stock has a market capitalization of $4.51 billion, a PE ratio of -179.63 and a beta of 0.43. The company has a debt-to-equity ratio of 1.43, a current ratio of 2.84 and a quick ratio of 1.88. The business’s 50-day moving average is $14.31 and its 200 day moving average is $11.07.

Amicus Therapeutics (NASDAQ:FOLD) last released its quarterly earnings results on Friday, February 20th. The biopharmaceutical company reported $0.10 EPS for the quarter, missing analysts’ consensus estimates of $0.13 by ($0.03). Amicus Therapeutics had a negative net margin of 4.27% and a positive return on equity of 4.15%. The business had revenue of $185.21 million for the quarter, compared to the consensus estimate of $185.00 million. During the same period in the previous year, the company earned $0.09 EPS. The company’s revenue for the quarter was up 23.7% on a year-over-year basis. Sell-side analysts forecast that Amicus Therapeutics, Inc. will post 0.15 earnings per share for the current year.

Analyst Ratings Changes

Several equities analysts recently issued reports on the company. Leerink Partners lowered Amicus Therapeutics from an “outperform” rating to a “market perform” rating and reduced their price target for the stock from $17.00 to $14.50 in a research report on Monday, December 29th. Weiss Ratings reissued a “sell (d-)” rating on shares of Amicus Therapeutics in a research note on Monday, December 29th. Cantor Fitzgerald cut shares of Amicus Therapeutics from an “overweight” rating to a “hold” rating and cut their target price for the stock from $21.00 to $14.50 in a report on Friday, December 19th. Needham & Company LLC downgraded shares of Amicus Therapeutics from a “buy” rating to a “hold” rating in a research note on Friday, December 19th. Finally, Zacks Research lowered shares of Amicus Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Monday, January 26th. Three equities research analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, Amicus Therapeutics has an average rating of “Hold” and a consensus price target of $15.39.

Amicus Therapeutics Profile

Amicus Therapeutics (NASDAQ:FOLD) is a biopharmaceutical company focused on the discovery, development and commercialization of treatments for rare and orphan diseases. The company specializes in pharmacological chaperones and gene therapy approaches designed to address the underlying causes of lysosomal storage disorders. Its proprietary technology platform integrates structure‐based drug design with precision medicine to identify small molecules that stabilize misfolded proteins and restore cellular function.

The company’s lead marketed product, Galafold (migalastat), is an oral pharmacological chaperone approved in the United States, European Union and other territories for the treatment of Fabry disease in patients with amenable genetic variants.